David Smoller, PhD

Director

 

Prior to joining Horizon Discovery as their Chief Business officer. David was CEO of Sage Labs. Sage Labs was a life science company developing genetically modified Rodents using gene editing technologies. Sage was acquired in 2014 by Horizon Discovery.

Previous to SAGE Labs, David was Chief Scientific Officer for Sigma Alrdich. David joined Sigma-Aldrich in June 2004 as Vice President of R&D, a role in which he helped to expand Sigma-Aldrich’s leadership position through the development of new and innovative products for Life Science and High Technology research. In October of 2005, he expanded his role from R&D to operations, heading up both R&D and operations for the Research Biotech Business Unit of Sigma-Aldrich. In July of 2007 he was then promoted to President of the Research Biotech Business Unit within Sigma Life Science to drive the implementation of a number of commercial initiatives in the Functional Genomics, Proteomics, Regenerative Medicine, Cell Biology and Animal Models and services areas.

Prior to joining Sigma-Aldrich, David was CEO and President of ProteoPlex, Inc., a seed stage spinout focusing on functional genomics. He founded ProteoPlex, Inc. in 2001 and led the St. Louis-based company through its product development and final acquisition by EMD Biosciences (Merck KGaA).

In 1992, David founded Genome Systems, Inc. in St. Louis, which provided the scientific community with access to genome project-related technologies. He stayed at the helm of the organization during its acquisition in 1996 by the Incyte Corporation, based in Palo Alto, California, and was promoted to Senior Vice President and leader of the organization’s St. Louis operations, where he grew the staff to more than 250 people. During his tenure at Incyte, his responsibilities expanded and included the management of the $150 million Genomic Business Unit. This responsibility included overseeing the management of 700 hundred employees, as well as managing the strategic planning, product marketing, and research and development strategy of the unit.

David earned a doctorate degree in Molecular Biology and a bachelor’s degree in Biology from Emory University in Atlanta, Georgia. He completed a postdoctoral fellowship at Washington University in St. Louis, Missouri, in the Drosophila Genome project and a postdoctoral fellowship at Monsanto Corporation. He is a Board member of the Center of Emerging Technologies, the St. Louis Academy of Science, Washington University National Research Advisory Council, and The Advisory Council of the Biomedical Engineering Department of Washington University. As well as a number of Start up biotech companies.